Divesiran: A New Treatment for Polycythemia Vera Under Investigation image

Divesiran: A New Treatment for Polycythemia Vera Under Investigation

By Jimena Vicencio, MD Jimena is a medical doctor currently studying a bachelor in journalism. Posted on: Nov 16, 2026

Living with polycythemia vera (PV) often means dealing with frequent doctor visits to have blood drawn. This routine blood removal, called a phlebotomy, helps keep the blood from getting too thick. However, new clinical trial results show that an experimental treatment called divesiran could soon offer patients a way to control their red blood cell counts without relying as heavily on blood draws.

What is divesiran?

Divesiran (also known as SLN124) is a novel RNA-based therapy designed to control how the body uses iron. It works by silencing a specific gene in the liver called TMPRSS6. When this gene is turned down, the liver produces more hepcidin, which is the body's primary hormone for managing iron levels.

Because bone marrow needs iron to make red blood cells, boosting hepcidin limits the amount of available iron. This natural bottleneck slows down the overproduction of red blood cells at the source.

Why is divesiran relevant for people with polycythemia vera?

Today, there are no approved drugs that directly stop the body from making too many red blood cells in polycythemia vera. Current options rely mainly on repeated phlebotomies, which can be exhausting and disruptive or general medications that reduce blood cell counts. Divesiran offers a targeted alternative that directly addresses blood thickness while improving patient quality of life.


The SANRECO Phase 2 Trial

The latest findings from the Phase 2 SANRECO clinical trial highlight several significant benefits:

  • High response rate: 88% of patients treated with divesiran had safe blood thickness levels (hematocrit under 45%) without needing a any blood draws between weeks 18 and 36, compared to 19% of people taking a placebo.

  • Over 36 weeks, patients receiving divesiran averaged only 0.2 phlebotomies, compared to an average of 2.1 in the placebo group. This is equivalent to 1 phlebotomy roughly every 3.5 years, compared to placebo undergoing a phlebotomy every 4 months.

  • Strong results were seen whether the injection was given once every 6 weeks (93.8% response rate) or once every 12 weeks (81.3% response rate).

  • Divesiran was well tolerated. The most common side effects were minor, temporary reactions at the injection site, with no major new safety concerns reported.

  • People reported improvements in overall symptoms as well as healthier iron levels in their blood test results after taking divesiran.

What Comes Next?

Because divesiran has received Fast Track and Orphan Drug designations from the U.S. FDA, its development is moving forward quickly. Silence Therapeutics (the company that is developing devesiran) plans to launch a larger Phase 3 clinical trial in the first half of 2027 to further confirm these results before seeking official approval.

While divesiran remains an investigational therapy, the SANRECO results mark a exciting milestone in the search for targeted, disease-modifying options in polycythemia vera.

Stay tuned for more updates on polycythemia vera

Create your free account and keep track of your health with a personal health record, community events, and news.

CREATE YOUR ACCOUNT 

Sources: